Lowest Price Guaranteed From USD 4,799
Published
January 2023
Pages
315
View Count
11188
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global TIL therapy market is estimated to be worth $0.09 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period. The global TIL therapy market is a growing market within the cell therapy market and is estimated to grow at a CAGR of 40% during the forecast period. Over the years, various studies have validated the successful use of tumor infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor. These lymphocytes selectively mediate the elimination of tumor cells. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL therapy market is likely to witness significant growth during the forecast period.
The Global TIL Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication (Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia and Cervical Carcinoma), Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the companies focused on the development of TIL cell therapy. The market report answers many key questions related to this industry.
Modified tumor infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL therapies. Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Additionally, this emerging class of biologics is believed to possess the potential to cater to the unmet pharmacological needs, across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.
Over 75 TIL cell therapy are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs. Both industry and non-industry players have demonstrated keen interest in the development of novel tumor infiltrating lymphocytes as therapeutics. Further, melanoma emerged as the most popular target indication in TIL therapy market. More than 95% of the TIL therapy candidates that are being developed to target a wide range of disease indications are autologous in nature.
With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate (CAGR) of 40% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by TIL therapy targeting melanoma and head and neck carcinoma. Iovance Biotherapeutics’ drug lifileucel is expected to be the first TIL therapy to receive FDA approval in 2023. Iovance Biotherapeutics first submitted a rolling BLA for lifileucel in the treatment of patients with metastatic melanoma to the FDA in August 2022 and received FDA feedback for additional information in November 2022. The company expects to complete the rolling BLA submission for lifileucel in Q1 2023. TIL cell therapy for treatment of solid tumors has also reached phase II clinical trials and will drive the market growth in the long-term, owing to the presence of a number of drug developers evaluating this indication.
Additionally, close to 90% of the market is anticipated to be captured by players based in North America and Europe, in 2035. Within North America, the US is expected to see the first TIL therapy approval in 2023. Once approved, lifileucel will continue to drive the market growth in the short term. According to the National Cancer Institute statistic, there were an estimated 1,413,976 people living with melanoma of the skin in the US in 2020. Although melanoma only accounts for 1% of all the skin cancers in the US, it still accounts for a high mortality amongst all skin cancer. There have been novel, effective treatment options available for melanoma approved by the FDA that have changed the treatment paradigm for melanoma; however, there is need for more effective therapeutics. Overall, we are led to believe that the global TIL therapy market is poised to witness significant growth in the foreseen future.
A number of TIL therapy developers have also started evaluating genetically engineered tumor infiltrating lymphocytes. The companies have developed proprietary technology platforms for engineering TILs. In December 2022, US based Instil Bio discontinued its TIL therapy ITIL-168, in phase 2 clinical trials for metastatic melanoma, stating its intent to focus on genetically-engineered TIL therapy instead of unmodified tumor infiltrating lymphocytes. As such, the company’s lead molecule now is ITIL-306, an autologous TIL cell therapy engineered using their CoStAR platform. The TIL therapy is in phase I clinical trial for solid tumors. Another US based company, Obsidian Therapeutics has a proprietary cytoDRIVE® platform for development of engineered TIL therapy. Their lead candidate, OBX-115, is an engineered TIL being tested in phase I clinical trials in patients with metastatic melanoma. Such technological developments is likely to contribute to the improvement in the safety and efficacy of TIL therapies, driving the TIL therapy market growth.
TIL therapy market has a number of academic / non-industry players actively conducting and sponsoring clinical trials. The lead TIL cell therapy against melanoma is in phase III clinical trials at the Netherlands Cancer Institute. The team of researchers presented positive results from phase 3 trial at ESMO Congress in September 2022, in which the TIL therapy was evaluated in patients with melanoma with Ipilimumab used as a comparator drug. The Netherlands Cancer Institute plans to gain EMA approval for its TIL therapy and ensure its access to melanoma patients at affordable prices, without the involvement of pharmaceutical industry. In line with its plans, the institute has also set up a manufacturing unit within its premises. The approval can introduce a new business model of Academic Pharma, motivating the other institutes to also take the lead in ensuring market access to tumor infiltrating lymphocytes.
A growing interest in TIL cell therapy is reflected from the increase in the partnerships focused on R&D of such therapies. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013. Further, in the last 10 years, close to 95 TIL therapy clinical trials have been registered across different geographies. Mostly driven by the need for effective treatment options for cancer, the TIL therapy pipeline is expected to steadily grow over the forecast period. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives. The market includes a number of start-ups and the funding will provide them necessary support to move their drug candidates towards commercialization. These developments will support the market growth of TIL therapy during the forecast period.
Examples of key players engaged in this domain (which have also been captured in this report) include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis, Incyte Corporation, Instil Bio, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals and Prometheus Laboratories. This market report includes an easily searchable excel database with all TIL therapy / tumor infiltrating lymphocyte developers, both industry and academic institutes, worldwide.
Several recent developments have taken place in the field of TIL therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different attrributes / segments as defined in the below table:
| Key Report Attributes | Details | |
|
Forecast Period |
2023 – 2035 |
|
| Base Year | 2022 | |
| CAGR | 40% | |
|
Target Indication |
Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia, Cervical Carcinoma |
|
|
Key Players |
Iovance Biotherapeutics, Bristol-Myers Squibb, Instil Bio, Lytix Biopharma, CAR-T (Shanghai) Cell Biotechnology, Incyte Corporation, Prometheus Laboratories |
|
|
Key Geographical Regions |
North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, Rest of the World |
|
|
Key Companies Profiled |
Cellectis, Cellular Biomedicine Group, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals |
|
|
Customization Scope |
15% Free Customization Option (equivalent to 5 analyst working days) |
|
| PowerPoint Presentation (Complimentary) |
Available |
|
|
Excel Data Packs (Complimentary) |
Market Landscape Analysis, Clinical Trial Analysis, KOL Analysis, Partnership and Collaboration Analysis, Funding and Investment Analysis, Patent Analysis, Market Forecast and Opportunity Analysis |
|
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the report includes:
One of the key objectives of the research report was to estimate the current market size and the future growth potential of tumor infiltrating lymphocytes over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of TIL therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TIL therapy market, wherein both the current and upcoming opportunity is segmented across target indication (melanoma, head and neck carcinoma, chronic lymphocytic leukemia, sarcoma, hepatocellular carcinoma, breast cancer, acute myeloid leukemia and cervical carcinoma), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.
Answer: TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor.
Answer: As of date, there is no approved TIL therapy. The first TIL therapy is expected to receive FDA approval in 2023.
Answer: Some of the side effects noted in TIL therapy clinical trials are fever, chills and shortness of breath. Few other adverse events mainly associated with chemotherapy or IL-2 treatment given before and with TIL cell therapy are neutropenia, lymphopenia and coagulopathy.
Answer: The global TIL therapy market is expected to grow at a compound annual growth rate (CAGR) of 40% during the forecast period 2023-2035.
Answer: Europe is growing at the highest CAGR, over the forecast period 2023-2035.
Answer: Close to 30 industry and non-industry players are currently evaluating the potential of over 75 TIL- therapies for the treatment of various oncological and non-oncological disorders.
Answer: Melanoma is likely to capture the maximum share (51%) of the TIL therapy market in 2035.
Answer: Currently, R&D agreements, licensing agreements, and manufacturing agreements are the common types of partnerships inked by developers involved in the tumor infiltrating lymphocytes market.
Answer: More than 70% of the filed patents were patent applications, while around 28% were granted patents. Of the total granted applications, more than 95% were filed in the US.
Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.7.1. Development History
3.7.2. Development of TILs Therapy
3.8. Key Benefits and Roadblocks
3.9. Concluding Remarks
4. TIL-BASED THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TIL-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Key Target Indications
4.2.5. Analysis by Source of T-Cells
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
4.3. TIL-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. CLINICAL TRIAL ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. TIL-based Therapies: Clinical Trial Analysis
5.3.1. Analysis by Trial Registration Year
5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
5.3.3. Analysis by Trial Status
5.3.4. Analysis by Trial Registration Year and Trial Status
5.3.5. Analysis by Trial Phase
5.3.6. Analysis by Trial Phase and Enrolled Patient Population
5.3.7. Analysis by Target Patient Segment
5.3.8. Analysis by Type of Sponsor / Collaborator
5.3.9. Analysis by Study Design
5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
5.3.12. Word Cloud Analysis: Emerging Focus Areas
5.3.13. Analysis of Clinical Trials by Geography
5.3.14. Analysis of Enrolled Patient Population by Geography
6. KEY OPINION LEADERS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. TIL-based Therapies: Key Opinion Leaders
6.4.1. Analysis by Type of Organization
6.4.2. Analysis by Affiliated Organization
6.4.3. Analysis by Qualification
6.4.4. Analysis by Geographical Location of KOLs
6.4.5. KOL Activeness versus KOL Strength
6.4.6. Most Prominent KOLs: Analysis by RA score
6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
7. TIL-BASED THERAPY PROFILES
7.1. Chapter Overview
7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
7.2.1. Therapy Overview
7.2.2. Clinical Trial Information
7.2.3. Clinical Trial Endpoints
7.2.4. Clinical Trial Results
7.2.5. Estimated Sales Revenues
7.3. LN-145 (Iovance Biotherapeutics)
7.3.1. Therapy Overview
7.3.2. Clinical Trial Information
7.3.3. Clinical Trial Endpoints
7.3.4. Clinical Trial Results
7.3.5. Estimated Sales Revenues
7.4. ITIL-168 (Instil Bio)
7.4.1. Therapy Overview
7.4.2. Clinical Trial Information
7.4.3. Clinical Trial Endpoints
7.4.4. Clinical Trial Results
7.4.5. Estimated Sales Revenues
7.5. LTX-315 (Lytix Biopharma)
7.5.1. Therapy Overview
7.5.2. Clinical Trial Information
7.5.3. Clinical Trial Endpoints
7.5.4. Clinical Trial Results
7.5.5. Estimated Sales Revenues
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. TIL-based Therapies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Most Popular Products: Analysis by Number of Partnerships
8.3.6. Most Active Industry Players: Analysis by Number of Partnerships
8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. Intercontinental and Intracontinental Agreements
8.3.8.2. International and Local Deals
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. TIL-based Therapies: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Investor
9.3.5. Most Active Players: Analysis by Number of Instances
9.3.6. Most Active Investors: Analysis by Amount Invested
9.3.7. Analysis of Amount Invested by Geography
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. TIL-based Therapies: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis By Patent Application Year
10.3.3. Analysis by Geography
10.3.4. Analysis by Type of Player
10.3.5. Analysis by CPC Symbols
10.3.6. Word Cloud Analysis: Emerging Focus Areas
10.3.7. Leading Players: Analysis by Number of Patents
10.3.8. TIL-based Therapies: Patent Benchmarking
10.3.9. Analysis By Patent Characteristics
10.3.10. TIL-based Therapies: Patent Valuation
11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Overview of Cell Therapy Manufacturing
11.3. Cell Therapy Manufacturing Models
11.3.1. Centralized Manufacturing Model
11.3.2. Decentralized Manufacturing Model
11.4. Scalability of Cell Therapy Manufacturing Processes
11.4.1. Scale-Up
11.4.2. Scale-Out
11.5. Types of Cell Therapy Manufacturers
11.6. Key Challenges Related to Manufacturing of Cell Therapies
11.7. Important Factors for Cell Therapy Manufacturing
11.7.1. Characterization
11.7.2. Cost of Goods
11.8. Automation of Cell Therapy Manufacturing Process
11.9. Cell Therapy Manufacturing Supply Chain
11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
11.11. Regulatory Landscape
11.12. Future Perspectives
12. COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the High Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. Based on Associated Costs
12.3.2. Based on Availability of Competing Products
12.3.3. Based on Patient Segment
12.3.4. Based on Opinions of Industry Experts
12.4. Reimbursement related Considerations for T-Cell Immunotherapies
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Key Assumptions and Forecast Methodology
13.4. Global TIL-Based Therapies Market, 2022-2035
13.4.1. TIL-based Therapies Market: Analysis by Target Indication
13.4.2. TIL-based Therapies Market: Analysis by Key Players
13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions
13.4.4. Product Wise Sales Forecast
13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
13.4.4.1.1. Sales Forecast (USD Million)
13.4.4.1.2. Net Present Value (USD Million)
13.4.4.1.3. Value Creation Analysis
13.4.4.2. LN-145 (Iovance Biotherapeutics)
13.4.4.2.1. Sales Forecast (USD Million)
13.4.4.2.2. Net Present Value (USD Million)
13.4.4.2.3. Value Creation Analysis
13.4.4.3. LTX-315 and TILs (Lytix Biopharma)
13.4.4.3.1. Sales Forecast (USD Million)
13.4.4.3.2. Net Present Value (USD Million)
13.4.4.3.3. Value Creation Analysis
13.4.4.4. TILs (Prometheus Laboratories)
13.4.4.4.1. Sales Forecast (USD Million)
13.4.4.4.2. Net Present Value (USD Million)
13.4.4.4.3. Value Creation Analysis
13.4.4.5. Donor Lymphocyte Infusion (Incyte)
13.4.4.5.1. Sales Forecast (USD Million)
13.4.4.5.2. Net Present Value (USD Million)
13.4.4.5.3. Value Creation Analysis
13.4.4.6. ITIL-168 (Instil Bio)
13.4.4.6.1. Sales Forecast (USD Million)
13.4.4.6.2. Net Present Value (USD Million)
13.4.4.6.3. Value Creation Analysis
13.4.4.7. IOV-2001 (Iovance Biotherapeutics)
13.4.4.7.1. Sales Forecast (USD Million)
13.4.4.7.2. Net Present Value (USD Million)
13.4.4.7.3. Value Creation Analysis
13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
13.4.4.8.1. Sales Forecast (USD Million)
13.4.4.8.2. Net Present Value (USD Million)
13.4.4.8.3. Value Creation Analysis
13.4.4.9. TILs (Bristol-Myers Squibb)
13.4.4.9.1. Sales Forecast (USD Million)
13.4.4.9.2. Net Present Value (USD Million)
13.4.4.9.3. Value Creation Analysis
14. COMPANY PROFILES
14.1. Chapter Overview
14.2. Cellectis
14.3. Cellular Biomedicine Group
14.4. Iovance Biotherapeutics
14.5. Lytix Biopharma
14.6. Phio Pharmaceuticals
15. CONCLUDING REMARKS
16. EXECUTIVE INSIGHTS
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TIL-based Therapies: Development Process
Figure 4.1 TIL-based Therapies: Distribution by Type of Developer
Figure 4.2 TIL-based Therapies: Distribution by Phase of Development
Figure 4.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 4.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 4.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 4.6 TIL-based Therapies: Distribution by Route of Administration
Figure 4.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 4.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 4.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 4.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 4.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 4.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Clinical Trial Analysis: Scope and Methodology
Figure 5.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Figure 5.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Figure 5.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 5.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 5.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 5.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 5.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 5.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 5.10 Clinical Trial Analysis: Distribution by Study Design
Figure 5.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 5.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 5.13 Word Cloud Analysis: Emerging Focus Areas
Figure 5.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 5.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 5.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 5.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 6.1 KOL Analysis: Distribution by Type of Organization
Figure 6.2 KOL Analysis: Distribution by Affiliated Organization
Figure 6.3 KOL Analysis: Distribution by Qualification
Figure 6.4 KOL Analysis: Distribution by Geography
Figure 6.5 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 6.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 6.7 Most Prominent KOLs: Distribution by RA Score
Figure 6.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 6.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 7.1 LN-144: Estimated Sales Revenues
Figure 7.2 LN-145: Estimated Sales Revenues
Figure 7.3 ITIL-168: Estimated Sales Revenues
Figure 7.4 LTX-315: Estimated Sales Revenues
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 8.7 Most Popular Products: Distribution by Number of Partnerships
Figure 8.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.11 Partnerships and Collaborations: International and Local Deals
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 9.7 Most Active Players: Distribution by Number of Instances
Figure 9.8 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 10.3 Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 10.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
Figure 10.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Figure 10.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
Figure 10.7 Patent Analysis: Distribution by Geography
Figure 10.8 Patent Analysis: Distribution by Type of Player
Figure 10.9 Patent Analysis: Distribution by CPC Symbols
Figure 10.10 Word Cloud Analysis: Emerging Focus Areas
Figure 10.11 Leading Industry Players: Distribution by Number of Patents
Figure 10.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 10.15 Patent Analysis: Distribution by Patent Age
Figure 10.16 TIL-based Cell Therapies: Patent Valuation Analysis
Figure 11.1 Steps for Manufacturing Cell Therapies
Figure 11.2 Centralized Manufacturing: Process Model
Figure 11.3 Decentralized Manufacturing: Process Model
Figure 11.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 11.5 Cell Therapy: Challenges and Drivers
Figure 11.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 11.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 12.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 13.1 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 13.2 TIL-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 13.3 TIL-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 13.4 TIL-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 13.5 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.6 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.7 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 13.8 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 13.9 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 13.10 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 13.11 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.12 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 13.13 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Market Landscape
Figure 15.2 Concluding Remarks: Clinical Trial Analysis
Figure 15.3 Concluding Remarks: Key Opinion Leaders
Figure 15.4 Concluding Remarks: Partnerships & Collaborations
Figure 15.5 Concluding Remarks: Funding and Investment Analysis
Figure 15.6 Concluding Remarks: Patent Analysis
Figure 15.7 Concluding Remarks: Market Forecast
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
Table 3.3 Retroviral Vectors: Salient Features
Table 3.4 Lentiviral Vectors: Salient Features
Table 4.1 TIL-based Therapies: Clinical Pipeline
Table 4.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 4.3 TIL-based Therapies: Preclinical Pipeline
Table 4.4 List of TIL-based Developers
Table 6.1 TIL-based Therapies: List of Principal Investigators
Table 7.1 TIL Cell Therapies: List of Therapies Profiled
Table 7.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 7.3 LN-144: Clinical Trial Information
Table 7.4 LN-144: Clinical Trial Endpoints
Table 7.5 LN-144: Clinical Trial Results
Table 7.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 7.7 LN-145: Clinical Trial Information
Table 7.8 LN-145: Clinical Trial Endpoints
Table 7.9 LN-145: Clinical Trial Results
Table 7.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 7.11 ITIL-168: Clinical Trial Information
Table 7.12 ITIL-168: Clinical Trial Endpoints
Table 7.13 ITIL-168: Clinical Trial Results
Table 7.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 7.15 LTX-315: Clinical Trial Information
Table 7.16 LTX-315: Clinical Trial Endpoints
Table 7.17 LTX-315: Clinical Trial Results
Table 8.1 List of Partnerships and Collaborations, 2005-2022
Table 9.1 List of Funding and Investments, 2007-2022
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.1 Assessment Strategies for Different Manufacturing Processes
Table 11.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 12.1 Price of Marketed Gene / Cell Therapies
Table 12.2 Price of Marketed Targeted Drugs
Table 12.3 TIL-based Therapies: Expert Opinions on Pricing
Table 12.4 TIL-based Therapies: Reimbursement Landscape
Table 13.1 TIL-based Therapies: List of Forecasted Molecules
Table 13.2 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.3 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.4 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.5 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.6 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 13.7 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 13.8 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 13.9 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 13.10 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 13.11 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 13.12 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 13.13 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 13.14 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.15 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.16 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 13.17 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 13.18 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 13.19 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 14.1 Leading TIL-based Therapy Developers
Table 14.2 Cellectis: Company Profile
Table 14.3 Cellular Biomedicine Group: Company Profile
Table 14.4 Iovance Biotherapeutics: Company Profile
Table 14.5 Lytix Biopharma: Company Profile
Table 14.6 Phio Pharmaceuticals: Company Profile
Table 17.1 TIL-based Therapies: Distribution by Type of Developer
Table 17.2 TIL-based Therapies: Distribution by Phase of Development
Table 17.3 TIL-based Therapies: Distribution by Therapeutic Area
Table 17.4 TIL-based Therapies: Distribution by Key Target Indications
Table 17.5 TIL-based Therapies: Distribution by Source of T-Cells
Table 17.6 TIL-based Therapies: Distribution by Route of Administration
Table 17.7 TIL-based Therapies: Distribution by Dosing Frequency
Table 17.8 TIL-based Therapies: Distribution by Target Patient Segment
Table 17.9 TIL-based Therapies: Distribution by Type of Therapy
Table 17.10 Most Active Industry Players: Analysis by Number of TIL-based Therapies
Table 17.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 17.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 17.13 TIL-based Therapy Developers: Distribution by Company Size
Table 17.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Table 17.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Table 17.18 Clinical Trial Analysis: Distribution by Trial Status
Table 17.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 17.20 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Table 17.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 17.22 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 17.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24 Clinical Trial Analysis: Distribution by Study Design
Table 17.25 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.26 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.27 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.28 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 17.29 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.31 KOL Analysis: Distribution by Type of Organization
Table 17.32 KOL Analysis: Distribution by Affiliated Organization
Table 17.33 KOL Analysis: Distribution by Qualification
Table 17.34 KOL Analysis: Distribution by Geography
Table 17.35 Most Prominent KOLs: Distribution by RA Score
Table 17.36 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 17.37 LN-144: Estimated Sales Revenues
Table 17.38 LN-145: Estimated Sales Revenues
Table 17.39 ITIL-168: Estimated Sales Revenues
Table 17.40 LTX-315: Estimated Sales Revenues
Table 17.41 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.43 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Table 17.44 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.45 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Table 17.46 Most Popular Products: Distribution by Number of Partnerships
Table 17.47 Most Active Industry Players: Distribution by Number of Partnerships
Table 17.48 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 17.49 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 17.50 Partnerships and Collaborations: Distribution of International and Local Deals
Table 17.51 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018-2022
Table 17.52 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018-2022 (USD Million)
Table 17.53 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.54 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 17.55 Funding and Investment Analysis: Distribution by Type of Investor
Table 17.56 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 17.57 Most Active Players: Distribution by Number of Instances
Table 17.58 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.59 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 17.60 Patent Analysis: Distribution by Type of Patent
Table 17.61 Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 17.62 Patent Analysis: Cumulative Distribution Patent Application Year
Table 17.63 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 17.64 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Table 17.65 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 17.66 Patent Analysis: Distribution by Geography
Table 17.67 Patent Analysis: Distribution by Type of Player
Table 17.68 Patent Analysis: Distribution by CPC Symbols
Table 17.69 Leading Industry Players: Distribution by Number of Patents
Table 17.70 Leading Non-Industry Players: Distribution by Number of Patents
Table 17.71 Leading Patent Assignees: Distribution by Number of Patents
Table 17.72 Patent Analysis: Distribution by Patent Age
Table 17.73 TIL-based Therapies: Patent Valuation Analysis
The following companies and organizations have been mentioned in the report:
Source 1: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/til-therapy
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES